Immunotherapy with pembrolizumab deemed cost-effective for advanced melanoma in Hong Kong – EurekAlert (press release)

Zennie Abraham / Zennie62
Zennie Abraham / Zennie62

Immunotherapy with pembrolizumab deemed cost-effective for advanced melanoma in Hong Kong
EurekAlert (press release)
“This is the first study to address the cost-effectiveness of checkpoint inhibitors in the management of advanced cancer in Hong Kong,” said lead author Dr Herbert Loong, Clinical Assistant Professor in the Department of Clinical Oncology of The

…read more

From:: Hong Kong News By Google News

About the Author

Zennie Abraham
Zennie Abraham | Zennie Abraham or "Zennie62" is the founder of Zennie62Media which consists of zennie62blog.com and a multimedia blog news aggregator and video network, and 78-blog network, with social media and content development services and consulting. Zennie is a pioneer video blogger, YouTube Partner, social media practitioner, game developer, and pundit. Note: news aggregator content does not reflect the personal views of Mr. Abraham.

Be the first to comment on "Immunotherapy with pembrolizumab deemed cost-effective for advanced melanoma in Hong Kong – EurekAlert (press release)"

Leave a comment

Your email address will not be published.




Open

Maria Ayerdi Kaplan

Close